Celgene (CELG) Acquires Swiss Biotech EngMab for $600M - EndPoint News

September 30, 2016 11:06 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Celgene (NASDAQ: CELG) has agreed to acquire Swiss biotech EngMab for $600 million, EndPoint news reported.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Mergers and Acquisitions

Related Entities

Definitive Agreement

Add Your Comment